| scholarly article | Q13442814 |
| P2093 | author name string | Kohji Miyazaki | |
| Takao Ohtsuka | |||
| Takao Ide | |||
| Yasuo Koga | |||
| Yoshihiko Kitajima | |||
| Atsushi Miyoshi | |||
| Kazuma Ohtaka | |||
| Mayumi Mitsuno | |||
| P2860 | cites work | Hypoxia Attenuates the Expression of E-Cadherin via Up-Regulation of SNAIL in Ovarian Carcinoma Cells | Q24685207 |
| Hypoxia--a key regulatory factor in tumour growth | Q29547318 | ||
| Emerging multipotent aspects of hepatocyte growth factor | Q41066829 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| neoplastic invasiveness | Q112498967 | ||
| pancreatic cancer | Q212961 | ||
| P304 | page(s) | 2750-2759 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway | |
| P478 | volume | 119 |
| Q34423550 | Angiogenesis - still a worthwhile target for breast cancer therapy? |
| Q26862741 | Anti-angiogenesis and metastasis: a tumour and stromal cell alliance |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q39651237 | Cancer cell‐derived IL‐1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells |
| Q35201636 | Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression |
| Q37621828 | Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. |
| Q91366841 | Dihydroartemisinin-Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity |
| Q48219198 | Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? |
| Q50231382 | Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment |
| Q39739616 | Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells |
| Q36785933 | FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer |
| Q35527125 | GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and axillary lymph node metastases |
| Q30845111 | GenCLiP: a software program for clustering gene lists by literature profiling and constructing gene co-occurrence networks related to custom keywords |
| Q51152435 | HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. |
| Q54572474 | HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. |
| Q26781273 | Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge |
| Q47152778 | Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. |
| Q35767934 | Human breast cancer histoid: an in vitro 3-dimensional co-culture model that mimics breast cancer tissue |
| Q39588661 | Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer |
| Q37801762 | Hypoxia and hypoxia-inducible factors: master regulators of metastasis |
| Q39502908 | Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. |
| Q55285319 | Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. |
| Q46453398 | Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer |
| Q24603371 | Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells |
| Q53689233 | Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. |
| Q46636420 | Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer |
| Q36142366 | Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. |
| Q36805595 | KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib |
| Q26766065 | Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells |
| Q39121333 | MET: roles in epithelial-mesenchymal transition and cancer stemness |
| Q89666737 | Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer |
| Q33718025 | Molecular mechanisms of resistance to tumour anti-angiogenic strategies |
| Q27012236 | Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma |
| Q63888766 | Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. |
| Q44995197 | Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. |
| Q37409275 | Signal transduction in pancreatic stellate cells |
| Q39922278 | Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1. |
| Q33946966 | Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. |
| Q37978193 | Targeting MET in cancer: rationale and progress |
| Q35764455 | The Apoptotic Effect of HIF-1α Inhibition Combined with Glucose plus Insulin Treatment on Gastric Cancer under Hypoxic Conditions |
| Q38806970 | The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma |
| Q41779542 | The Critical Impact of HIF-1a on Gastric Cancer Biology |
| Q35078950 | The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects |
| Q36815851 | The autism risk genes MET and PLAUR differentially impact cortical development |
| Q37807243 | The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox |
| Q48635543 | The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival |
| Q48181172 | The hypoxic tumour microenvironment |
| Q37187529 | The tumor microenvironment and metastatic disease |
| Q37179521 | The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis |
| Q36357873 | Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans |
| Q39505379 | Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. |
| Q54310714 | Tumour budding is associated with hypoxia at the advancing front of colorectal cancer. |
| Q24620228 | Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment |
| Q54375509 | Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. |
| Q53787748 | [Resistance to anti-angiogenic therapy: a clinical and scientific current issue]. |
| Q38393333 | cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance |
Search more.